7GQ Stock Overview
Develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Paragon 28, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.45 |
| 52 Week High | US$13.30 |
| 52 Week Low | US$4.06 |
| Beta | 1.01 |
| 11 Month Change | 117.74% |
| 3 Month Change | 30.34% |
| 1 Year Change | 2.16% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -38.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7GQ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.6% | 2.4% | 0.8% |
| 1Y | 2.2% | -5.0% | 9.1% |
Return vs Industry: 7GQ exceeded the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: 7GQ underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 7GQ volatility | |
|---|---|
| 7GQ Average Weekly Movement | 14.6% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7GQ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7GQ's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 574 | Albert DaCosta | paragon28.com |
Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis.
Paragon 28, Inc. Fundamentals Summary
| 7GQ fundamental statistics | |
|---|---|
| Market cap | €800.88m |
| Earnings (TTM) | -€53.50m |
| Revenue (TTM) | €233.43m |
3.4x
P/S Ratio-14.7x
P/E RatioIs 7GQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7GQ income statement (TTM) | |
|---|---|
| Revenue | US$245.00m |
| Cost of Revenue | US$55.11m |
| Gross Profit | US$189.89m |
| Other Expenses | US$246.03m |
| Earnings | -US$56.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 77.51% |
| Net Profit Margin | -22.92% |
| Debt/Equity Ratio | 79.3% |
How did 7GQ perform over the long term?
See historical performance and comparison